Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.
about
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorderPain Assessment--Can it be Done with a Computerised System? A Systematic Review and Meta-AnalysisCharacteristics of binge eating disorder in relation to diagnostic criteriaEvidence-Based Assessment of Obsessive-Compulsive DisorderThe Use and Effectiveness of Mobile Apps for Depression: Results From a Fully Remote Clinical Trial.The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research.Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder.Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsA randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agThe efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled studyEfficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case StudyReliability and validity of the Sheehan Disability Scale modified for pathological gamblingBurden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010.Somatic symptoms in patients with cancer experiencing pain or depression: prevalence, disability, and health care useFunctional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidateMultiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.Research aimed at improving both mood and weight (RAINBOW) in primary care: A type 1 hybrid design randomized controlled trial.The Psychological and Medical Factors Associated With Untreated Binge Eating DisorderLevomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study.Treatment of traumatised refugees with basic body awareness therapy versus mixed physical activity as add-on treatment: Study protocol of a randomised controlled trial.An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatmentImplementing a knowledge application program for anxiety and depression in community-based primary mental health care: a multiple case study research protocol.Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.Is early-onset in major depression a predictor of specific clinical features with more impaired social function?Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing.Quality of life in borderline patients comorbid with anxiety spectrum disorders - a cross-sectional study.Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.Prevalence and age-of-onset distributions of DSM IV mental disorders and their severity among school going Omani adolescents and youths: WMH-CIDI findings.Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.Self-awareness of functional impairment in individuals at clinical high-risk for psychosis.The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.Feedback versus no feedback in improving patient outcome in group psychotherapy for eating disorders (F-EAT): protocol for a randomized clinical trial.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder.Early switching strategies in antidepressant non-responders: current evidence and future research directions.Implementing routine outcome measurement in psychiatric rehabilitation services in Israel.
P2860
Q24564427-4B77BD30-0523-4A5C-92F6-2B65D2C93854Q26752745-7F78CF04-710C-45EE-AECE-DFC050D425FCQ28066684-23B0A27E-CDCB-49D0-B4CD-D0711457D238Q28077756-D8B09E1F-F2CD-4A63-B8F5-D29155816E4DQ33451957-1917FB86-E87E-4FE8-9AFD-47051A460F25Q33622133-9D05D542-7205-4925-9ED5-0ED15BDB7BCCQ33685298-A5DB2C4E-14F7-4E35-9F41-42985A1F2707Q33718213-9EC5E0C1-BA85-4476-98C0-4C38AEB3D789Q34041642-BABC981D-B741-4681-A0C0-7B98F5CD0DF1Q34531579-BDCFCD9C-AFA6-4845-A01B-7FCC97E717C3Q34629315-0627002D-14B6-4B26-951B-68299749F413Q34672417-6D5400FC-11A1-4C92-B82D-CD396ABF12FBQ34712964-79136547-D6B8-4FA7-9DD9-D85E5875C5A4Q34788519-35E309C8-C8A7-455F-83B6-9770CDD9A7E6Q35040553-C5DE6086-A909-478D-AFD1-B007366D72EBQ35216630-4B581585-849F-4AE9-93AB-3AA127F110F8Q35579008-9A4EA7A0-3DE4-4F8C-B7ED-DA6DB8D7310BQ35755924-98B9A805-5E01-49D7-9DBB-823DAD869F59Q35957450-AE6C7DF1-56C7-4909-9744-EB7E3AA35739Q36028291-5EB12CAD-9FDC-4097-AF68-D0E1AECA74B4Q36083249-25265C21-F5D9-46DD-8BBB-D8EDC032C6FCQ36168261-67D61CF4-B61A-40FC-9BE2-53A8D82C6D25Q36202904-96B0D4DA-5CF9-4CCA-91DB-E35A4E6F9416Q36332538-5B71D79E-CF53-4487-A96A-65CBBB4636CFQ36477623-65393CD6-4D92-43E0-8265-E5800909925EQ36735812-07B59B11-BD92-45FE-9CE0-499E7B99872BQ36755321-5BB6EE5D-16D5-4034-B4A1-756E5EADEFDBQ36804807-7F69AA4B-7F21-4189-A880-24A3E2D7D592Q37148276-BF7FD6AD-F255-4C5B-A5C0-56C7394BF60CQ37154964-9DBF2E70-B0F8-4E19-B81C-CBB23CD69E2AQ37308842-FED33C2D-A3D2-4784-B2AF-F3C9E4F9CB54Q37387323-082B9B82-CD24-42AE-9C8D-8DB65D754484Q37404814-A00AD2FE-8169-4055-B457-D4F6A9AE9E09Q37610169-8E351D0F-821A-47A7-945F-7BB37C24398FQ37694366-116A7ADA-5AE4-4585-9821-E9A733EB5404Q37733802-6BDCCE07-470F-43AB-9AB5-F22D9C46E5CAQ37808483-D1414920-CFD4-4B3D-B725-7F44E4C63D19Q38027189-DE2956F5-1FF9-4506-8720-C88EBE5273F0Q38211978-12BFE4C4-B3DA-4B11-B4D7-9B07B783DAEAQ38390793-EFFBADF4-0338-40EF-8DF0-E14776BBC52E
P2860
Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Assessing treatment effects in ...... the Sheehan Disability Scale.
@ast
Assessing treatment effects in ...... the Sheehan Disability Scale.
@en
Assessing treatment effects in ...... the Sheehan Disability Scale.
@nl
type
label
Assessing treatment effects in ...... the Sheehan Disability Scale.
@ast
Assessing treatment effects in ...... the Sheehan Disability Scale.
@en
Assessing treatment effects in ...... the Sheehan Disability Scale.
@nl
prefLabel
Assessing treatment effects in ...... the Sheehan Disability Scale.
@ast
Assessing treatment effects in ...... the Sheehan Disability Scale.
@en
Assessing treatment effects in ...... the Sheehan Disability Scale.
@nl
P1476
Assessing treatment effects in ...... the Sheehan Disability Scale.
@en
P2093
David V Sheehan
Kathy Harnett Sheehan
P356
10.1097/YIC.0B013E3282F2B4D6
P577
2008-03-01T00:00:00Z